

AMENDMENTS TO THE CLAIMS

1(Original). (2S)-2-Amino-2-cyclohexyl-1-((3RS)-3-fluoro-pyrrolidin-1-yl)-ethanone or (S)-2-amino-2-cyclohexyl-1-(3,3-difluoro-pyrrolidin-1-yl)-ethanone, or a pharmaceutically acceptable salt thereof.

2(Original). A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

3(Currently Amended). A pharmaceutical composition comprising a) ~~a first compound comprising~~ a compound of claim 1, or a pharmaceutically acceptable salt of said first compound of claim 1; and b) a second compound ~~comprising~~ selected from the group consisting of insulin or an insulin analog; insulinotropin; a biguanide; an α -2 antagonist or imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an α -glucosidase inhibitor; a β -agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; a vanadate, vanadium complex or peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somatostatin analog; an inhibitor of renal glucose; an antilipolytic agent; ~~or~~ and a pharmaceutically acceptable salt of said second compound.

4(Cancelled).

5(Original). A kit comprising: a) a first dosage form comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof; b) a second dosage form comprising insulin or an insulin analog; insulinotropin; a biguanide; an α -2 antagonist or imidazoline; a glitazone; an aldose reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase inhibitor; a fatty acid oxidation inhibitor; an α -glucosidase inhibitor; a β -agonist; a phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; a vanadate, vanadium complex or peroxovanadium complex; an amylin antagonist; a glucagon antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a somatostatin analog; an inhibitor of renal glucose; an antilipolytic agent; or a pharmaceutically acceptable salt thereof; and c) a container.

6(Original). A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of dipeptidyl peptidase inhibition a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

7(Currently Amended). A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of dipeptidyl peptidase-IV inhibition a therapeutically effective amount of a pharmaceutical composition of any one of claims 2, ~~3 or 4~~ 2 or 3.

8(Currently Amended). A method of treating a condition ~~mediated by dipeptidyl peptidase-IV inhibition~~ in a mammal, wherein said condition is selected from the group consisting of Type 1 diabetes, Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, and obesity, comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

9(Currently Amended). A method of treating a condition ~~mediated by dipeptidyl peptidase-IV inhibition~~ in a mammal, wherein said condition is selected from the group consisting of Type 1 diabetes, Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, and obesity, comprising administering to said mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition of any one of claims 2, ~~3 or 4~~ 2 or 3.

10(Cancelled).

11(Currently Amended). The method of claim 10 wherein the condition treated is Type ~~4~~ 2 diabetes.

12(Original). A prodrug of a compound of claim 1, or a pharmaceutically acceptable salt of said prodrug.